10Y annualized return is
very good
at 13.3% per year
VRTX has met or exceeded earnings expectations in
the majority of
recent quarters (7/10)
High Price-to-Sales Ratio
Strong Gross Profit Margin
Negative Price-to-Earnings Ratio
High EV/EBITDA
Get access to all key takeaways, detailed financial metrics, and comprehensive stock analysis with our premium subscription.
Already have an account? Sign in
Vertex Pharmaceuticals appears to be in a robust position with a solid revenue base and a diversified pipeline that offers promising future growth. However, the increasing R&D expenses and market challenges should be monitored closely as the company strives to capitalize on its innovative therapies.
Analysis Date: February 10, 2025
Last Updated: May 29, 2025
Past performance does not guarantee future results. The data presented is indicative and may not be updated in real-time.
Vertex Pharmaceuticals is a biotechnology company that creates medicines for people with cystic fibrosis, a genetic condition that affects the lungs and digestive system. They have developed several important drugs, like SYMDEKO and KALYDECO, that help patients manage their symptoms. In addition to cystic fibrosis, Vertex is also working on treatments for other serious health issues, such as diabetes and kidney diseases. The company sells its products mainly through special pharmacies and hospitals in the U.S. and around the world.
Core Products
Business Type
Business to Business
Competitive Advantages
Discover all competitive advantages and strategic moats that protect VRTX's market position.
View Premium AnalysisKey Business Risks
Get comprehensive insight into all key business risks that could impact VRTX's performance.
Access Full Risk AnalysisLatest News
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
When the stock market is highly volatile, many investors flock to assets that offer stability but dismal growth prospects. However, you don't necessar...
President Trump isn't a fan of Fed Chairman Jerome Powell, despite nominating Powell to replace Janet Yellen in 2017. Trump recently called Powell a "...
Trailing Twelve Months (TTM) values provide a view of the company's performance over the last year.
Benjamin Graham's value investing approach focuses on finding stocks with a significant margin of safety between their intrinsic value and market price.
Access Benjamin Graham's value investing criteria, intrinsic value calculations, and margin of safety analysis
Trailing Twelve Months (TTM) values provide a view of the company's performance over the last year.
Profitability metrics measure a company's ability to generate earnings relative to its revenue, operating costs, and other relevant metrics. Higher values generally indicate better performance.
Access detailed profitability metrics with visual gauges and benchmarks
Access detailed analysis of profitability strengths and positive performance indicators
Upgrade to PremiumAccess detailed analysis of profitability weaknesses and areas of concern
Upgrade to PremiumFinancial health metrics assess a company's ability to meet its financial obligations and its overall financial stability.
Access detailed financial health metrics with visual gauges and risk assessments
Access detailed analysis of financial health strengths and stability indicators
Upgrade to PremiumAccess detailed analysis of financial health weaknesses and risk factors
Upgrade to PremiumMeeting Expectations
Higher values indicate better execution and credibility
Recent Results
View complete earnings history and detailed performance analysis
Upgrade to PremiumEPS
Revenue
Insider trading data shows purchase and sale activities by company executives and board members.
Insider trading patterns can provide insights into how company executives and board members view the stock's future prospects.
Get complete insider sentiment analysis with detailed trading patterns, sentiment indicators, and trend insights